SEC Comment Letter 0000000000-23-010013 to SYNLOGIC, INC. (SYBX)
SYNLOGIC, INC.
Date: Sept. 11, 2023 · CIK: 0001527599 · Accession: 0000000000-23-010013
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-37566
Letter
United States securities and exchange commission logo September 11, 2023 Michael Jensen Chief Financial Officer Synlogic, Inc. 301 Binney St., Suite 402 Cambridge, MA 02142 Re:Synlogic, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 29, 2023 File No. 001-37566 Dear Michael Jensen: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-K for the fiscal year ended December 31, 2022 Management's Discussion and Analysis of Financial Condition and Results of Operations Financial Overview Research and Development Expense, page 83 1.Please revise your future filings to break out the amounts incurred for Internal research and development expenses by nature or type of expense (i.e. employee related expenses) for each period presented. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Vanessa Robertson at 202-551-3649 or Daniel Gordon at 202-551-3486 with any questions.
FirstName LastNameMichael Jensen Comapany NameSynlogic, Inc. September 11, 2023 Page 2 FirstName LastName Michael Jensen Synlogic, Inc. September 11, 2023 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
September 11, 2023
Michael Jensen
Chief Financial Officer
Synlogic, Inc.
301 Binney St., Suite 402
Cambridge, MA 02142
Re:Synlogic, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 29, 2023
File No. 001-37566
Dear Michael Jensen:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment. In our comment, we may ask you to provide us
with information so we may better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Form 10-K for the fiscal year ended December 31, 2022
Management's Discussion and Analysis of Financial Condition and Results of Operations
Financial Overview
Research and Development Expense, page 83
1.Please revise your future filings to break out the amounts incurred for Internal research
and development expenses by nature or type of expense (i.e. employee related
expenses) for each period presented.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
You may contact Vanessa Robertson at 202-551-3649 or Daniel Gordon at 202-551-3486
with any questions.
FirstName LastNameMichael Jensen
Comapany NameSynlogic, Inc.
September 11, 2023 Page 2
FirstName LastName
Michael Jensen
Synlogic, Inc.
September 11, 2023
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences